期刊文献+

益气养阴通络方联合阿帕替尼和替加氟治疗晚期胃癌临床观察 被引量:14

Clinical Observation on Treatment of Advanced Gastric Cancer with Yiqi Yangyin Tongluo Decoction Combined with Apatinib and Tegafur
原文传递
导出
摘要 目的:观察益气养阴通络方联合阿帕替尼和替加氟治疗二线及以上药物治疗失败的气阴两虚型晚期胃癌的临床疗效、安全性及对患者生活质量的影响。方法:选择安徽医科大学第一附属医院2017年5月—2018年3月收治的中医辨证属气阴两虚夹瘀型、既往未使用靶向治疗及替加氟口服化疗的晚期癌症患者60例;每组纳入30例患者,对照组采用阿帕替尼联合替加氟方案进行治疗,观察组在对照组的基础上加用益气养阴通络方,比较两组临床疗效、中医证候积分评价、生活质量评估、不良反应发生率、治疗前后T淋巴细胞亚群数量差异、治疗前后血清细胞因子等指标。结果:两组临床疗效的差异比较无统计学意义,但观察组的客观缓解率、疾病控制率高于对照组;观察组中医证候改善、生活质量较前提高明显要优于对照组,两组不良反应发生率、治疗前后免疫功能、治疗前后血清细胞因子具有差异性。结论:益气养阴通络方结合西医化疗药及靶向药治疗晚期胃癌可减毒、增强患者免疫功能、减少炎性反应、提高生活质量,具有重要的临床意义。 Objective:To observe the clinical efficacy,safety and quality of life of patients with advanced gastric cancer with deficiency of Qi and Yin due to Yiqi Yangyin Tongluo Decoction combined with apatinib and tegafur in the treatment of second-line or above drug failure. Methods:We selected patients with terminal cancer who had not previously used targeted therapy and tegafur oral chemotherapy in the TCM differentiation syndromes of the first affiliated hospital of Anhui medical university from May 2017 to March 2018. 30 patients were included in each group. The control group was treated with apatinib combined with tegafur. The observation group was supplemented with Yiqi Yangyin Tongluo Decoction on the basis of the control group. The clinical efficacy,evaluation of TCM syndrome score,life quality assessment,incidence of adverse reaction,difference of the number of T lymphocyte subsets,serum cytokines before and after treatment were compared between the two groups. Results:There was no significant difference in clinical efficacy between the two groups,but the objective remission rate and disease control rate in the observation group was higher than that control group;the improvement in TCM symptoms and life quality after treatment in the observation group was significantly higher than that control group,and the difference was statistically significant. There was a difference in the incidence of adverse reactions in the two groups,the immune function and the serum cytokines before and after treatment between the two groups. Conclusion:Yiqi Yangyin Tongluo Decoction combined with Western medicine chemotherapeutic drugs and targeted drugs in the treatment of advanced gastric cancer can achieve detoxification,enhance the immune function of patients,reduce inflammatory reaction and improve the quality of life,which has important clinical significance.
作者 倪田田 李平 NI Tiantian;LI Ping(Anhui University of Traditional Chinese Medicine,Hefei 230038,Anhui,China;The First Affiliated Hospital of Anhui Medical University,Hefei 230022,Anhui,China)
出处 《辽宁中医药大学学报》 CAS 2019年第4期120-123,共4页 Journal of Liaoning University of Traditional Chinese Medicine
基金 国家自然科学基金项目(81673908)
关键词 益气养阴通络方 气阴两虚夹瘀型 阿帕替尼 替加氟 晚期胃癌 Yiqi Yangyin Tongluo Decoction Qi-Yin deficiency with blood-stasis syndrome apatinib tegafur advanced gastric cancer
  • 相关文献

参考文献3

二级参考文献25

  • 1蔡善荣,郑树,张苏展.不同年龄组大肠癌预后多因素分析的比较[J].中华肿瘤杂志,2005,27(8):483-485. 被引量:41
  • 2Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108 [PMID: 15761078 D0!:.10.B322(canjclin.55.2.74].
  • 3Grvalos C, Garcia-Escobar I, Garcta-Alfonso P, Cassinello J, Mal6n D, Carrato A. Adjuvant che- motherapy for stages II, III and IV of colon cancer. Clin Transl Oncol 2009; 11:526-533 [PMID: 19661027 DOI: 10.1007/s12094-009-0397-8].
  • 4Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol ]A, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw2009; 7:778-831 [PMID: 19755046].
  • 5Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Nat1 Compr Canc Netw 2009; 7:838-881 [PMID: 19755047].
  • 6Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002; 7:288-323 [PMID: 12185293 DOI: 10.1634/theoncologist.7-4-288].
  • 7’uJ周际昌,谢惠民.新编抗肿瘤药物临床治疗手册.第一版北京:中国协和医科大学出版社,2005:36.37.
  • 8Bajetta E, Di Bartolomeo M, Buzzoni R, Mariani L, Zilembo N, Ferrario E, Lo Vullo S, Aitini E, Isa L, Barone C, Jacobelli S, Recaldin E, Pinotti G, Iop A. Uracil/ftorafur/leucovorin combined with iri- notecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Br J Cancer 2007; 96:439-444 [PMID: 17245343 DOI: 10.1038/sj.bjc.6603493].
  • 9Hsiao SC, Lin JF, Chuang MT, Lee YA, Wu DL. Ret- rospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxali- platin combined with oral tegafur/uracil (UFT)/leu- covorin (LV) in patients with metastatic colorectal cancer. Int Surg 2009; 94:298-303 [PMID: 20302025].
  • 10Andr6 T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gra- mont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-2351 [PMID: 15175436 DOI: 10.1056/NEJMoa032709].

共引文献57

同被引文献205

引证文献14

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部